1 |
Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008;165:721-730.
DOI
|
2 |
Gortz-Dorten A, Breuer D, Hautmann C, Rothenberger A, Dopfner M. What contributes to patient and parent satisfaction with medication in the treatment of children with ADHD? A report on the development of a new rating scale. Eur Child Adolesc Psychiatry 2011;20 Suppl 2(Suppl 2):S297-S307.
|
3 |
Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, et al. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosci 2009;63:167-175.
DOI
|
4 |
Kabore L, Muntner P, Chamot E, Zinski A, Burkholder G, Mugavero MJ. Self-report measures in the assessment of antiretroviral medication adherence: comparison with medication possession ratio and HIV viral load. J Int Assoc Provid AIDS Care 2015;14:156-162.
DOI
|
5 |
Wang PS, Benner JS, Glynn RJ, Winkelmayer WC, Mogun H, Avorn J. How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf 2004;13:11-19.
DOI
|
6 |
So YK, Noh JS, Kim YS, Ko SG, Koh YJ. The reliability and validity of Korean parent and teacher ADHD Rating Scale. J Korean Neuropsychiatr Assoc 2002;41:283-289.
|
7 |
Kim HI, Kim BN, Cho SC, Shin MS, Yoo HJ, Kim JW, et al. Change of quality of life in children with ADHD after 12 weeks OROS-methylphenidate treatment. J Korean Acad Child Adolesc Psychiatry 2012;23:103-108.
DOI
|
8 |
Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991;148:564-577.
DOI
|
9 |
McGough JJ, Smalley SL, McCracken JT, Yang M, Del'Homme M, Lynn DE, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 2005;162:1621-1627.
DOI
|
10 |
Kim YJ, Oh SY, Lee J, Moon SJ, Lee WH, Bahn GH. Factors affecting adherence to pharmacotherapy in childrenwith attention-deficit hyperactivity disorder: a retrospective study. J Korean Acad Child Adolesc Psychiatry 2010;21:174-181.
DOI
|
11 |
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington, VA: American Psychaitric Association;2013.
|
12 |
Kim HW, Kim E, Kim JH, Park J, Bahn GH, Lee YJ, et al. The revised Korean practice parameter for the treatment of attentiondeficit hyperactivity disorder (III)-pharmacological treatment-. J Korean Acad Child Adolesc Psychiatry 2017;28:70-83.
DOI
|
13 |
Kim JS, Kim BN, Cho SC, Shin MS, Yoo HJ, Kim JW, et al. The side effects and correlates of OROS-methylphenidatein the treatment of children and adolescents with ADHD. J Korean Acad Child Adolesc Psychiatry 2010;21:63-71.
DOI
|
14 |
Kim YS, So YK, Noh JS, Choi NK, Kim SJ, Koh YJ. Normative data on the Korean ADHD Rating Scales (K-ARS) for parents and teacher. J Korean Neuropsychiatr Assoc 2003;42:352-359.
|
15 |
Yang L, Cao Q, Shuai L, Li H, Chan RC, Wang Y. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. Int J Neuropsychopharmacol 2012;15:15-26.
DOI
|
16 |
Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006;13:e50-e62.
|
17 |
Atzori P, Usala T, Carucci S, Danjou F, Zuddas A. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol 2009;19:673-681.
DOI
|
18 |
Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL. Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health 2008;2:25.
DOI
|
19 |
Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-784.
DOI
|
20 |
Ni HC, Lin YJ, Gau SS, Huang HC, Yang LK. An open-label, randomized trial of methylphenidate and atomoxetine treatment in adults with ADHD. J Atten Disord 2017;21:27-39.
DOI
|
21 |
Hong M, Lee WH, Moon DS, Lee SM, Chung US, Bahn GH. A 36 month naturalistic retrospective study of clinic-treated youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2014;24:341-346.
DOI
|
22 |
Kim B, Lee JS, Kim EJ, Sung HM, Shin YM, Hwang SH, et al. Treatment adherence of osmotic-controlled release oral delivery system methylphenidate in Korean children and adolescents with attention-deficit hyperactivity disorder. J Korean Acad Child Adolesc Psychiatry 2014;25:65-72.
DOI
|
23 |
Song J, Kim B, Son JW, Yoo HK, Lee SI, Han DH, et al. Efficacy of OROS methylphenidate for the treatment of ADHD. J Korean Acad Child Adolesc Psychiatry 2012;23(Suppl 3):S12-S23.
|
24 |
Yildiz O, Sismanlar SG, Memik NC, Karakaya I, Agaoglu B. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry Hum Dev 2011;42:257-269.
DOI
|
25 |
Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 2011;11:176.
DOI
|
26 |
Kim BS, Park EJ. An observational multi-center study for evaluation of efficacy, safety and parental satisfaction of methylphenidateOROS in children with ADHD. J Korean Acad Child Adolesc Psychiatry 2005;16:279-285.
|